Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.
Location: United States, Delaware, Wilmington
Employees: 11-50
Total raised: $30M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | Shavit Cap... | shavitcapi... |
| - | Israel Bio... | ibf.fund |
| - | Arc Ventur... | arc-vc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.05.2019 | Series B | $30M | - |
Mentions in press and media 9
| Date | Title | Description | Source |
| 27.03.2024 | Ayala Pharmaceuticals Announces Completion of Sale of AL102 ... | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS),... | ibf.fund/n... |
| 06.02.2024 | Immunome To Acquire AL102, A Phase 3 Asset for the Treatment... | AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile BOTHELL, ... | ibf.fund/n... |
| 19.02.2021 | Ayala Pharmaceuticals Announces $25 Million Strategic Financ... | Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023 Funds Expected to Supp... | globenewsw... |
| 30.06.2020 | ‘Covid Put Everything On Steroids,’ Says Prominent Healthtec... | When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of tech... | forbes.com... |
| 12.05.2020 | Ayala Pharmaceuticals Announces Closing of Initial Public Of... | Ayala is an Arc Ventures portfolio company since 2018 . The official press release can be found on t... | arc-vc.com... |
| 28.05.2019 | Ayala Pharmaceuticals Secures $30M in Series B Funding | Ayala Pharmaceuticals, Inc., a Wilmington, DE-based clinical-stage company developing medicines for ... | finsmes.co... |
| 28.05.2019 | Ayala Pharmaceuticals Raises $30 Million in Series B Financi... | REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-sta... | citybizlis... |
| 28.05.2019 | Ayala Pharmaceuticals Raises $30 Million in Series B Financi... | REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-sta... | archive.ci... |
| 25.05.2019 | Ayala Pharmaceuticals Raises $30 Million | - | amoon.fund... |